4Feuer G.A, Shevchuk M, Calanog A. Normal-sized ovary carcinoma syndrom. Obstet Gynecol,1989,73(5 Pt 1):786-792.
5Takekawa Y, Kimura M, Sakakibara M, et al. Pathological,cytological and immunohistochemical study of normal-sized ovary carcinoma syndrom. Rinsho Byori, 2001,49:66-70.
6Kuwashima Y, Uehara T, Kurosumi M, et al. Pathological aspects of normal-sized ovarian carcinoma. Eur J Gynaecol Oncol, 1996,17:17-23.
7Kebapci M, Vardareli E, Adapinar B, et al. CT findings and serum CA125 levels in malignant peritoneal mesothelioma:report of 11 new cases and review of literature. Eur Radiol, 2003,13:2620-2626.
8Barbieri PG, Marinaccio A, Festa R, et al. Survival analysis of malignant mesothelioma treated in Brescia,northern Italy,1982-2000. Epidemiol Prev, 2004,28:107-113.
9Hotta T, Taniguchi K, Kobayashi Y, et al. Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma. Hepatogastroenterology, 2004,51:1073-1083.
10Yamazaki T, Hatano H, Suzuki A, et al. Normal-sized ovary carcinoma syndrome: histopathological analysis of 14 cases. Nippon Sanka Fujinka Gakkai Zasshi. 1995,47:27-34.
5Iyer RB,Balachandran A,Devine CE,et al.PET/CT and cross sectional imaging of gynecologic malignancy[J].Cancer Imaging,2007,7 Spec No A:S130-S138.
6García Velloso MJ,Boán García JF,Villar Luque LM,et al.F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence.Comparison with CT scan and CA 125[J].Rev Esp Med Nucl,2003,22(4):217-223.
7Suga K,Kawakami Y,Hiyama A,et al.F-18 FDG PET-CT findings in a case of normal-sized ovarian cancer syndrome[J].Clin Nucl Med,2009,34(10):706-709.
8Hata K, Hata t, Makihara K, et al. Preoperative diagnostic im aging of normal-sized ovary carcinoma syndrome [J ]. Int J Gynaecol Obstet, 1991, 35(3):259-264.
9Suga K, Kawakami Y, Hiyama A,et al. F-18 FDG PETCT findings in a case of normal-sized ovarian cancer syndrome[J]. Clin Nucl Mad, 2010, 34(10) :706-709.
10Marcus CS, Maxwell GL, Darcy KM, et al. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer[J]. J Cancer, 2014,5(1) :25-30.
